IGF2BP3 and esophageal cancer: An investigator-initiated phase 2 study on three HLA-A*24:02-restricted peptides from URLC10, KOC1, and cell division cycle-associated protein 1 (CDCA1) demonstrated prolonged survival of patients with esophageal cancer presenting pathologically positive nodes and curatively resected after preoperative therapy [10].